Skip to main content
. 2015 Jan 23;4(3):e994446. doi: 10.4161/2162402X.2014.994446

Figure 2.

Figure 2

(See previous page). (G) CD16+ NK-92 cells were used in an ADCC assay to determine the ability of cetuximab or rituximab to mediate clearance of EGFRt/4H11-28z/IL-12 CAR T cells. The samples were analyzed by flow cytometry for the decrease in percentage of CAR T cells with the antibody compared to CAR T cells in the absence of antibody. EGFRt/4H11-28z/IL-12 CAR T cells showed increased ADCC when treated with cetuximab compared to rituximab (p < 0.05). Cetuximab did not induce ADCC on 4H11-28z/IL-12 CAR T cells. Data shown is mean percentage of ADCC (±SEM) from three independent experiments.